drugset / Trial / NCT00387738

Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults

NCT00387738 ↗

Phase 2 Terminated 738 enrolled Dynavax Technologies Corporation
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to find out if a new investigational vaccine, TOLAMBA™, is safe and effective in reducing the symptoms of ragweed allergy.

Timeline

Start
2006-04
Primary completion
2007-05
Completion
2008-03

Outcome

Outcome not reported

Stopped: “Interim data indicated that subjects exhibited no meaningful allergic disease during the first ragweed season, making it impossible to measure treatment effect.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate Oligonucleotide (other) — Subcutaneous